Paraneoplastik Miyastenia Gravis'te Titin Pozitifliğinin Rolü

Abstract

Miyastenia gravis (MG), klinik gidişatı büyük ölçüde otoantikor profiliyle şekillenen otoimmün bir hastalıktır. Özellikle ileri yaş başlangıçlı olgularda ve timoma varlığında saptanan anti-titin antikorlarının, hastalık şiddeti ve kötü prognozla doğrudan ilişkili olduğu bilinmektedir. Bu olgu serisinde, geleneksel tanı testlerinin yetersiz kalabildiği atipik paraneoplastik MG vakalarında anti-titin antikorlarının tanısal değeri ve klinik yönetimdeki kritik rolüne dikkat çekilmesi amaçlanmıştır.

Keywords

• Miyasteni Gravis
• Paraneoplastik Sendromlar
• Otoantikorlar
• Timoma

The Role of Titin Positivity in Paraneoplastic Myasthenia Gravis

Abstract

Myasthenia gravis (MG) is an autoimmune disorder with a clinical course heavily influenced by the underlying autoantibody profile. The presence of anti-titin antibodies, particularly in late-onset cases and patients with thymoma, is directly associated with disease severity and a poorer prognosis. This case series aims to highlight the diagnostic value and critical role of anti-titin antibodies in the clinical management of atypical paraneoplastic MG cases, especially when conventional diagnostic tests are inconclusive.

Keywords

• Myasthenia Gravis
• Paraneoplastic Syndromes
• Autoantibodies
• Thymoma

Ethical Statement

Hastanın klinik bilgilerinin alınması ve yayınlanması için hastadan bilgilendirilmiş onam formu imzalı olarak alınmıştır.

References

1. 1. Hong Y, Li HF, Skeie GO, et al. Autoantibody profile and clinical characteristics in a cohort of Chinese adult myasthenia gravis patients. J Neuroimmunol. 2016; 298: 51-7.
2. 2. Romi F, Skeie GO, Aarli JA, et al. The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies. Arch Neurol. 2000; 57: 1596-600.
3. 3. Stefanou MI, Komorowski L, Kade S, et al. A case of late-onset, thymoma-associated myasthenia gravis with ryanodine receptor and titin antibodies and concomitant granulomatous myositis. BMC Neurol. 2016; 16: 172.
4. 4. Szczudlik P, Szyluk B, Lipowska M, et al. Antititin antibody in early- and late-onset myasthenia gravis. Acta Neurol Scand. 2014; 130: 229-33.
5. 5. Stergiou C, Lazaridis K, Zouvelou V, et al. Titin antibodies in "seronegative" myasthenia gravis--A new role for an old antigen. J Neuroimmunol. 2016; 292: 108-15.
6. 6. Somnier FE, Engel PJ. The occurrence of anti-titin antibodies and thymomas: a population survey of MG 1970-1999. Neurology. 2002; 59: 92-8.
7. 7. Chen XJ, Qiao J, Xiao BG, et al. The significance of titin antibodies in myasthenia gravis--correlation with thymoma and severity of myasthenia gravis. J Neurol. 2004; 251: 1006-11.
8. 8. Wang S, Shi D, Wu S, et al. Clinical characteristics of myasthenia gravis patients with coexistence of AChR and titin antibodies. Front Neurol. 2025; 16:1679404.

9. 9. Kim KH, Kim SW, Cho J, et al. Anti-titin antibody is associated with more frequent hospitalization to manage thymoma-associated myasthenia gravis. Front Neurol. 2022; 13: 978997.
10. 10. Stergiou C, Williams R, Fleming JR, et al. Immunological and Structural Characterization of Titin Main Immunogenic Region; I110 Domain Is the Target of Titin Antibodies in Myasthenia Gravis. Biomedicines. 2023; 11: 449.
11. 11. Thyagarajan JS, Almomani MH, Thatikonda N, et al. A Case of Myasthenia Gravis: A Paraneoplastic Syndrome or an Immune-Related Disorder? Cureus. 2025; 17: e78640.
12. 12. Oncel S, Tunc A. Unveiling Myasthenia Gravis: A comprehensive analysis of diagnostic tools and clinical insights. Dicle Med J 2023; 50: 482-9.